Congratulations to Will Burlingham, PhD, who received an NIH R21 grant for his project, “Exosome-mediated Tolerance in Combined Kidney and Stem Cell Transplantation.” This research will study whether renal transplant patients make tolerogenic virus-sized particles (known as extracellular vesicles (EV)) in response to their donor. It will also investigate if these patients, when deliberately weaned off immunosuppressive drug therapy in a clinical tolerance trial currently being run by Dixon Kaufman, MD, PhD, make even more EV, completely replacing their need for immunosuppressive drugs with their own “natural” form of immunosuppression.